Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation

Bone Marrow Transplantation

Volumn 21, Issue 10, 1998, Pages 995-1003

  Schmitz, N ^a   Bacigalupo, A ^b   Hasenclever, D ^c   Nagler, A ^d   Gluckman, E ^e   Clark, P ^m,n   Bourquelot, P ^f   Greinix, H ^g   Frickhofen, N ^h   Ringden O ⁱ   Zander, A ^j   Apperley, J F ^k   Gorin, C ^l   Borkett, K ^m,n   Schwab, G ^m,n   Goebel, M ^o   Russell, N H ^p   Gratwohl, A ^q  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e SAINT LOUIS HOSPITAL   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g UNIVERSITY OF VIENNA   (Austria)

^h UNIVERSITY OF ULM   (Germany)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY OF HAMBURG   (Germany)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

^l HÔPITAL SAINT ANTOINE   (France)

^m AMGEN LTD   (United Kingdom)

ⁿ Amgen Research GmbH   (Germany)

^o F HOFFMANN LA ROCHE LTD   (Switzerland)

^p NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^q UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

Allogeneic bone marrow transplantation; Allogeneic peripheral blood progenitor cell transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOKINE; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE PAIN; CANCER SURVIVAL; CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOMA; HEMATOPOIETIC STEM CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LENGTH OF STAY; LEUKAPHERESIS; LEUKEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NEUTROPHIL; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; STEM CELL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE;

EID: 0031775659     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701234     Document Type: Article

References (25)

1. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
2. Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
3. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
4. Azevedo WM, Aranha FJP, Gouvea JV et al. Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematological malignancies. Bone Marrow Transplant 1995; 16: 647-653.
5. Gratwohl A, Hermans J, Baldomero H, for the European Group for Blood and Marrow Transplantation (EBMT). Blood and marrow transplantation activity in Europe 1995. Bone Marrow Transplant 1997; 19: 407-419.
6. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-2800.
7. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host-disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
8. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
9. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
10. Wheatley K, Burnett AK, Goldstone AH et al on behalf of the MRC Adult and Childhood Leukaemia Working Parties: factors relating to the achievement of complete remission (CR) in younger patients with acute myeloid leukemia (AML) in the United Kingdom Medical Research Council (MRC) AML 10 Trial. Blood 1996; 88 (Suppl. 1): 214a (Abstr.).
11. Anderlini P, Przepiorka D, Champlin R. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1996; 88: 2819-2825.
12. Grigg AP, Roberts AW, Raunow H et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-4445.
13. Hasenclever D, Sextro M. Safety of allo PBSCT donors: biometrical considerations on monitoring long-term risks. Bone Marrow Transplant 1996; 17 (Suppl. 2): S28-S30.
14. Anderlini P, Körbling M, Dale D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903-908.
15. Buckner CD, Petersen FB, Bolonesi BA. Bone marrow donors. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, 1994, pp 259-269.
16. Auquier P, Macquart-Moulin G, Moatti JP et al. Comparison of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: leukacytapheresis and bone marrow harvest. Bone Marrow Transplant 1995; 16: 541-547.
17. Smith TJ, Hillner BE, Schmitz N et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral blood progenitor cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and Non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5-10.
18. Dreger P, Haferlach T, Eckstein V et al. G-CSF-mobilised peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994; 87: 609-613.
19. Körbling M, Huh YO, Durett A et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thyldim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-2848.
20. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
21. Pzrepiorka D, Anderlini P, Ippoliti C et al. Allogeneic blood stem cell transplantation in advanced hematologic. Bone Marrow Transplant 1997; 19: 455-460.
22. Russell JA, Brown C, Bowen T et al. Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 1996; 17: 703-708.
23. Majolino I, Saglio G, Scimé R et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancis. Bone Marrow Transplant 1996; 17: 555-560.
24. Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709.
25. Glass B, Uharek L, Zeis M et al. Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus-leukemia effect. Blood 1997; 90: 1694-1700.